A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses

Zhao, Hanjun; Zhou, Jie; Zhang, Ke; Chu, Hin; Liu, Dabin; Poon, Vincent Kwok Man; Chan, C. K.; Leung, Ho Chuen; Ng, Fai; Lin, Yu; Zhang, Anna Jin Xia; Jin, Dong Yan; Yuen, Kwok‐Yung; Zheng, Bo

doi:10.1038/srep22008

Cited by 148 publications

(166 citation statements)

References 39 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…Utilizing HAE cells infected with MERS-CoV, there was a significant reduction in viral replication and dsRNA level when cells were treated with K22 compound [47]. A novel peptide (P9) showed an in vitro activity against MERS-CoV at an IC50 of 5 μg/ml and more than 95% infection reduction at concentration higher than 25 μg/ml [48]. The two neurotransmitter antagonists (Chlorpromazine hydrochloride and triflupromazine hydrochloride) inhibit MERS-CoV infected Vero E6 cells [42].…”

Section: In Vitro Studiesmentioning

confidence: 99%

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Momattin

Al-Ali

Al‐Tawfiq

2019

Travel Medicine and Infectious Disease

114

View full text Add to dashboard Cite

Direct. Based on the inclusions and exclusions criteria, 30 articles were included in the final review and comprised: 22 in vitro studies, 8 studies utilizing animal models, 13 studies in humans, and one study included both in vitro and animal model. There are a few promising therapeutic agents on the horizon. The combination of lopinavir/ritonavir and interferon-beta-1b showed excellent results in common marmosets and currently is in a randomized control trial. Ribavirin and interferon were the most widely used combination and experience comes from a number of observational studies. Although, the data are heterogenous, this combination might be of potential benefit and deserve further investigation. There were no randomized clinical trials to recommend specific therapy for the treatment of MERS-CoV infection. Only one such study is planned for randomization and is pending completion. The study is based on a combination of lopinavir/ritonavir and interferon-beta-1b. A fully human polyclonal IgG antibody (SAB-301) was safe and well tolerated in healthy individuals and this agent may deserve further testing for efficacy. Conclusion: Despite multiple studies in humans there is no consensus on the optimal therapy for MERS-CoV. Randomized clinical trials are needed and potential therapies should be evaluated only in such clinical trials. In order to further enhance the therapeutic aroma for MERS-CoV infection, repurposing old drugs against MERS-CoV is an interesting strategy and deserves further consideration and use in clinical settings.

show abstract

Section: In Vitro Studiesmentioning

confidence: 99%

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Momattin

Al-Ali

Al‐Tawfiq

2019

Travel Medicine and Infectious Disease

114

View full text Add to dashboard Cite

show abstract

“…Of these software packages, citations have been found for JCat and OPTIMIZER for expression systems such as E. coli (Fahimi et al 2016;Guo et al 2016;Karkhah & Amani 2016;Zhao et al 2016), S. cerevisiae (Ask et al 2013;Guadalupe-Medina et al 2013;Li et al 2015;Milne et al 2015;Solis-Escalante et al 2013), N. benthamiana (Binder et al 2014), HEK293 cells (Shah et al 2015), B. subtilis (Reilman et al 2014), C. crescentus (Ko et al 2013), P. putida (Dammeyer et al 2013;Dammeyer et al 2011), S.…”

Section: Acc E P Ted P R E P R I Ntmentioning

confidence: 99%

Synthetic gene design—The rationale for codon optimization and implications for molecular pharming in plants

Webster

Teh

K.‐C.

2016

Biotech & Bioengineering

View full text Add to dashboard Cite

Degeneracy in the genetic code allows multiple codon sequences to encode the same protein. Codon usage bias in genes is the term given to the preferred use of particular synonymous codons. Synonymous codon substitutions had been regarded as "silent" as the primary structure of the protein was not affected; however, it is now accepted that synonymous substitutions can have a significant effect on heterologous protein expression. Codon optimization, the process of altering codons within the gene sequence to improve recombinant protein expression, has become widely practised.Multiple inter-linked factors affecting protein expression need to be taken into consideration when optimizing a gene sequence. Over the years, various computer programmes have been developed to aid in the gene sequence optimization process. However, as the rulebook for altering codon usage to affect protein expression is still not completely understood, it is difficult to predict which strategy, if any, will design the 'optimal' gene sequence.In this review, codon usage bias and factors affecting codon selection will be discussed and the evidence for codon optimization impact will be reviewed for recombinant protein expression using plants as a case study. These developments will be relevant to all recombinant expression systems, however, molecular pharming in plants is an area which has consistently encountered difficulties with low levels of recombinant protein expression, and should benefit from an evidence based rational approach to synthetic gene design. This article is protected by copyright. All rights reserved

show abstract

“…These derived peptides have shown activities against various micro-organisms [97,98]. For instance, the antiviral activity of 11 peptides derived from mouse ␤-defensin-4 was tested and one of them, P9, exhibited potent and broad spectrum antiviral effects against multiple respiratory viruses in vitro and in vivo, including influenza A virus H1N1, H3N2, H5N1, H7N7, H7N9, SARS-CoV and MERS-CoV [99].…”

Section: (B) Peptides Derived From Antimicrobial Peptidesmentioning

confidence: 99%

Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review

Mustafa

Balkhy

Gabere

2018

Journal of Infection and Public Health

133

129

View full text Add to dashboard Cite

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a highly pathogenic respiratory virus with mechanisms that may be driven by innate immune responses. Despite the effort of scientific studies related to this virus, Middle East Respiratory Syndrome (MERS) is still a public health concern. MERS-CoV infection has a high mortality rate, and to date, no therapeutic or vaccine has been discovered, that is effective in treating or preventing the disease. In this review, we summarize our understanding of the molecular and biological events of compounds acting as MERS-CoV inhibitors, the outcomes of existing therapeutic options and the various drugs undergoing clinical trials. Currently, several therapeutic options have been employed, such as convalescent plasma (CP), intravenous immunoglobulin (IVIG), monoclonal antibodies and repurposing of existing clinically approved drugs. However, these therapeutic options have drawbacks, thus the need for an alternative approach. The requirement for effective therapeutic treatment has brought the necessity for additional MERS treatments. We suggest that antimicrobial peptides (AMPs) may be used as alternative therapeutic agents against MERS-CoV infection. In addition, we propose the feasibility of developing effective agents by repurposing the existing and clinically approved anti-coronavirus and anti-viral peptide drugs.

show abstract

A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses

Cited by 148 publications

References 39 publications

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Synthetic gene design—The rationale for codon optimization and implications for molecular pharming in plants

Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review

Contact Info

Product

Resources

About